Galaxy Biomedical Investment Co., Ltd.

Symbol: 000806.SZ

SHZ

0.43

CNY

Market price today

  • -1.1415

    P/E Ratio

  • 0.0445

    PEG Ratio

  • 494.96M

    MRK Cap

  • 0.00%

    DIV Yield

Galaxy Biomedical Investment Co., Ltd. (000806-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.35%

Operating Profit Margin

-0.29%

Net Profit Margin

-0.41%

Return on Assets

-0.20%

Return on Equity

0.34%

Return on Capital Employed

-0.30%

Company general description and statistics

Sector: Technology
Industry: Electronic Components
CEO:Mr. Keyang Liu
Full-time employees:2031
City:Beihai
Address:Yinhe Software Technology Park
IPO:1998-04-16
CIK:

Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. The company produces and sells various transformer products, such as power, rectifier, and special transformers for use in metal smelting, electrochemistry, and power grid companies; and manufactures and sells electronic components, including displacement sensors, brake resistance boxes, radio frequency components, resistors, potentiometers, and others for use in aviation, aerospace, weapons, ships, AI intelligence, new energy, rail transit, communications, smart grids, instrumentation and other fields. It also offers animal products, and monoclonal antibody and targeted drugs, as well as drugs for the treatment of cancer and other diseases; laboratory equipment; and CRO, CAR-T technology and stem cell technology research and development, malignant cancer immune cell technology, and genetic testing services. The company also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.350% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.294%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.407%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.201% return, is a testament to Galaxy Biomedical Investment Co., Ltd.'s adeptness in optimizing resource deployment. Galaxy Biomedical Investment Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.343%. Furthermore, the proficiency of Galaxy Biomedical Investment Co., Ltd. in capital utilization is underscored by a remarkable -0.303% return on capital employed.

Stock Prices

Galaxy Biomedical Investment Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.63, while its low point bottomed out at $1.58. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Galaxy Biomedical Investment Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 000806.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 140.31% gauges short-term asset coverage for liabilities. The quick ratio (115.85%) assesses immediate liquidity, while the cash ratio (6.36%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio140.31%
Quick Ratio115.85%
Cash Ratio6.36%

Profitability Ratios

000806.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -39.22% underscores its earnings before tax deductions. The effective tax rate stands at -3.69%, revealing its tax efficiency. The net income per EBT, 103.69%, and the EBT per EBIT, 133.52%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -29.37%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-39.22%
Effective Tax Rate-3.69%
Net Income per EBT103.69%
EBT per EBIT133.52%
EBIT per Revenue-29.37%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.40, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding116
Days of Inventory Outstanding142
Operating Cycle560.88
Days of Payables Outstanding169
Cash Conversion Cycle392
Receivables Turnover0.87
Payables Turnover2.16
Inventory Turnover2.57
Fixed Asset Turnover4.02
Asset Turnover0.49

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.37, and free cash flow per share, -0.37, depict cash generation on a per-share basis. The cash per share value, 0.06, showcases liquidity position. A payout ratio of -0.03 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -0.41, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.37
Free Cash Flow per Share-0.37
Cash per Share0.06
Payout Ratio-0.03
Operating Cash Flow Sales Ratio-0.41
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-1.88
Short Term Coverage Ratio-1.96
Capital Expenditure Coverage Ratio-100.54
Dividend Paid and Capex Coverage Ratio-25.71

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 10.69%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.16, we discern the balance between debt and equity financing. The long-term debt to capitalization, -0.68%, and total debt to capitalization, -19.34%, ratios shed light on its capital structure. An interest coverage of -17.82 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio10.69%
Debt Equity Ratio-0.16
Long Term Debt to Capitalization-0.68%
Total Debt to Capitalization-19.34%
Interest Coverage-17.82
Cash Flow to Debt Ratio-1.88
Company Equity Multiplier-1.52

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.39, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.31, reflects the portion of profit attributed to each share. The book value per share, -1.14, represents the net asset value distributed per share, while the tangible book value per share, -1.23, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.39
Net Income Per Share-0.31
Book Value Per Share-1.14
Tangible Book Value Per Share-1.23
Shareholders Equity Per Share-1.14
Interest Debt Per Share0.20
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 33.56%, indicates top-line expansion, while the gross profit growth, 27.45%, reveals profitability trends. EBIT growth, 265.03%, and operating income growth, 265.03%, offer insights into operational profitability progression. The net income growth, 65.24%, showcases bottom-line expansion, and the EPS growth, 64.77%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth33.56%
Gross Profit Growth27.45%
EBIT Growth265.03%
Operating Income Growth265.03%
Net Income Growth65.24%
EPS Growth64.77%
EPS Diluted Growth64.77%
Weighted Average Shares Growth-0.02%
Weighted Average Shares Diluted Growth-0.02%
Dividends per Share Growth-1.26%
Operating Cash Flow Growth-24.78%
Free Cash Flow Growth16.87%
10-Year Revenue Growth per Share1.36%
5-Year Revenue Growth per Share46.12%
3-Year Revenue Growth per Share95.57%
10-Year Operating CF Growth per Share-107.12%
5-Year Operating CF Growth per Share49.31%
3-Year Operating CF Growth per Share-153.83%
10-Year Net Income Growth per Share-987.17%
5-Year Net Income Growth per Share-3391.12%
3-Year Net Income Growth per Share75.65%
10-Year Shareholders Equity Growth per Share-194.77%
5-Year Shareholders Equity Growth per Share-159.50%
3-Year Shareholders Equity Growth per Share-5301.11%
10-Year Dividend per Share Growth per Share-95.91%
5-Year Dividend per Share Growth per Share-69.06%
3-Year Dividend per Share Growth per Share-72.36%
Receivables Growth55.05%
Inventory Growth-28.83%
Asset Growth15.57%
Book Value per Share Growth-41.52%
Debt Growth65.57%
R&D Expense Growth18.24%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 2,055,996,496.4, captures the company's total value, considering both debt and equity. Income quality, 0.10, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 4.56%, highlights investment in innovation. The ratio of intangibles to total assets, 5.63%, indicates the value of non-physical assets, and capex to operating cash flow, 20.51%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value2,055,996,496.4
Income Quality0.10
Sales General and Administrative to Revenue0.02
Research and Development to Revenue4.56%
Intangibles to Total Assets5.63%
Capex to Operating Cash Flow20.51%
Capex to Revenue-0.46%
Capex to Depreciation-14.86%
Graham Number2.80
Return on Tangible Assets-17.78%
Graham Net Net-1.99
Working Capital419,219,228
Tangible Asset Value-1,355,818,640
Net Current Asset Value-1,786,526,423
Average Receivables968,418,516.5
Average Payables273,177,255.5
Average Inventory240,061,823.5
Days Sales Outstanding281
Days Payables Outstanding106
Days of Inventory On Hand74
ROIC-23.24%
ROE0.27%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.35, and the price to book ratio, -0.35, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.46, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -1.13, and price to operating cash flows, -1.14, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-0.35
Price to Book Ratio-0.35
Price to Sales Ratio0.46
Price Cash Flow Ratio-1.14
Price Earnings to Growth Ratio0.04
Enterprise Value Multiple3.58
Price Fair Value-0.35
Price to Operating Cash Flow Ratio-1.14
Price to Free Cash Flows Ratio-1.13
Price to Tangible Book Ratio-1.54
Enterprise Value to Sales1.35
Enterprise Value Over EBITDA7.74
EV to Operating Cash Flow-60.44
Earnings Yield-17.39%
Free Cash Flow Yield-2.12%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Galaxy Biomedical Investment Co., Ltd. (000806.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.141 in 2024.

What is the ticker symbol of Galaxy Biomedical Investment Co., Ltd. stock?

The ticker symbol of Galaxy Biomedical Investment Co., Ltd. stock is 000806.SZ.

What is company IPO date?

IPO date of Galaxy Biomedical Investment Co., Ltd. is 1998-04-16.

What is company current share price?

Current share price is 0.430 CNY.

What is stock market cap today?

The market cap of stock today is 494960096.000.

What is PEG ratio in 2024?

The current 0.045 is 0.045 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2031.